000			02136 a2200553 4500
005			20250516232640.0
264		0	_c20141211
008			201412s 0 0 fre d
022			_a1769-6658
024	7		_a10.1016/j.canrad.2014.07.147 _2doi
040			_aNLM _beng _cNLM
100	1		_aLévy, S
245	0	0	_a[Management of gliomas]. _h[electronic resource]
260			_bCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique _cOct 2014
300			_a461-7 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAge Factors
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Agents, Alkylating _xtherapeutic use
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBevacizumab
650	0	4	_aBrain Neoplasms _xgenetics
650	0	4	_aChemoradiotherapy _xadverse effects
650	0	4	_aChromosome Deletion
650	0	4	_aChromosomes, Human, Pair 1 _xgenetics
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aDacarbazine _xanalogs & derivatives
650	0	4	_aDose Fractionation, Radiation
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aGlioma _xgenetics
650	0	4	_aHumans
650	0	4	_aLomustine _xadministration & dosage
650	0	4	_aMethylation
650	0	4	_aMulticenter Studies as Topic
650	0	4	_aNeoplasm Proteins _xmetabolism
650	0	4	_aNeurosurgical Procedures
650	0	4	_aO(6)-Methylguanine-DNA Methyltransferase _xmetabolism
650	0	4	_aProcarbazine _xadministration & dosage
650	0	4	_aRadiotherapy Dosage
650	0	4	_aRadiotherapy, Intensity-Modulated _xadverse effects
650	0	4	_aTemozolomide
650	0	4	_aTreatment Outcome
650	0	4	_aVincristine _xadministration & dosage
700	1		_aChapet, S
700	1		_aMazeron, J-J
773	0		_tCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique _gvol. 18 _gno. 5-6 _gp. 461-7
856	4	0	_uhttps://doi.org/10.1016/j.canrad.2014.07.147 _zAvailable from publisher's website
999			_c24171878 _d24171878